As opposed to this, it was shown in ER+ (estrogen receptor-positive) /HER-negative (human epidermal growth factor receptor 2-negative) breast cancer that ADCK2 overexpression correlated with a worse outcome (abstract from AACR (cancerres.aacrjournals.org/content/80/4_Supplement/P2-11-17, accessed on 12 October 2021)). This evidence concerns the gene ADCK2 and breast carcinoma.